Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model

Talazoparib, a potent PARP inhibitor, induces synthetic lethality in BRCA-deficient cancers making it an attractive candidate for ovarian cancer treatment. However, its potency lends itself to side effects associated more closely with traditional chemotherapeutics than other clinically approved PARP...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Oncol
Hauptverfasser: Baldwin, Paige, Ohman, Anders W., Medina, Jamie E., McCarthy, Eric T., Dinulescu, Daniela M., Sridhar, Srinivas
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2019
Schlagworte:
Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524318/
https://ncbi.nlm.nih.gov/pubmed/31134152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00353
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge